Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
about
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryNeurologic indications for therapeutic plasma exchange: 2013 update.Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?Natalizumab in Multiple Sclerosis: Long-Term Management.Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisBroadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathyPseudovirus mimics cell entry and trafficking of the human polyomavirus JCPyV.Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis.Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.Progressive multifocal leukoencephalopathy after natalizumab discontinuation.Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin.Natalizumab-associated Progressive Multifocal Leukoencephalopathy in Patients with Multiple Sclerosis: A Mini Review
P2860
Q28555138-C280331F-999C-4E38-BB0E-C4FAEB922FFFQ30458271-3D3C693A-FD2A-41B8-867A-2F31E93E6039Q33562701-A2A05E54-A197-4401-B335-FB4C9C7D523FQ33754882-C7C70934-C3F7-4164-9BA8-1CB353C27814Q33773622-2D50C994-912E-40CE-8CB3-AE61ADF4E553Q34365360-C89B8807-EE0E-4B8A-BBEA-C82BD154F38DQ34457797-E574290E-E890-46C1-80F8-E02206A24156Q36389681-F34D5977-95B5-42D0-87CA-BDB7EC5CDB4AQ36484448-5272AB81-7F6B-41F4-8ECA-CFD6157F400DQ36764988-8FF9C774-EDA9-4174-B772-409960C8503DQ37361854-1D867D6A-463F-46F3-A09F-6E546EDCB59EQ38167347-0281FDFC-A7C8-400F-BA3D-3F6DBE7840FBQ38465723-C639BCDE-BB66-49A4-B6CD-60722B6A405DQ38630959-34236762-2D3B-4309-9EF1-DBBEAD1EFE4AQ38911206-68B55943-281A-4537-AEFB-96DBA4B76FA2Q39391443-A8D01FD5-B088-4BDB-AAEE-00733710540CQ39732691-0ADA5A7A-6984-44FB-84D0-4084C542545FQ42255115-DFEED58D-576D-4103-9D86-7DB95BC07ED6Q48821433-16071E6F-572F-4627-9108-2D5A566802CDQ50720019-2F2B0F3E-0113-48F2-9566-D6F58A14C061Q57495678-F4EDC835-4633-412F-8521-13FF5230EECE
P2860
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
@en
type
label
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
@en
prefLabel
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
@en
P1476
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
@en
P2093
Jeffery P Hogg
Kelly J Baldwin
P304
P356
10.1097/WCO.0B013E328360279F
P577
2013-06-01T00:00:00Z